The rate of synthesis of type I collagen, the major protein of the organic matrix of bone, can be assessed in humans in vivo by measuring the concentrations of the propeptide domains released during the physiological processing of its precursor, type I procollagen.
cancer, pleural fluid #{149} bone #{149} Coil domain. collagen
The rate of synthesis of type I collagen, the major protein of the organic matrix of bone, can be assessed in humans in vivo by measuring the concentrations of the propeptide domains released during the physiological processing of its precursor, type I procollagen.
The synthesis of fiber-forming collagens, i.e., collagen types 1-111and V, includes both extensive modification of the primary translation product intracellularly and proteolytic processing of the procollagen thus formed in the immediate vicinity of the cell membrane extracellularly [1, 2] . Two specific endoproteases are involved in releasing two large domains en bloc from the both ends of the procollagen molecule. Both PINP and PIIINP are present in nanomolar concentrations in human serum [5/ , from which they are cleared via the scavenger receptor in the liver endothelial cells /6/. However, antibodies to these proteins often also recognize other, smaller antigens in serum that are related to the most amino-terminal and most immunogenic part of a proal(I) or proal(III) chain, the so-called CoIl domain. in the case of PIIINP, much more of this smaller, monomeric antigen is present in serum than the intact propeptide, which tends to make the assays for PIIINP untitratable J7]. We have previously established a rapid, equilibrium RIA for PIIINP that is specific for the intact, trimeric antigen [8] .
Although several laboratories have reported assays for PINP, their specificities with respect to the intact and degraded forms of PINP have not been studied systematically.
The degradation products, being smaller, are subject to glomerular filtration, whereas the intact form has its specific receptor-mediated clearance in the liver, obviously leading to different life spans of the antigen forms in the blood. Also, the origins of the two forms can differ: For the homologous propeptide of type III procollagen PIIINP, at least, the intact form in the blood is not the precursor of the smaller form, whereas PIIINP CoIl is likely to be derived from the degradation of tissue pN-collagen [9] . The PINP assays published so far have been based on synthetic linear peptide sequences [10, Il] ;monomeric, al(I)-chain-derived propeptides isolated from human amniotic fluid [12, 13] ; or seemingly intact propeptides generated by collagenase treatment of procollagen isolated from MG-63 cell culture medium [14] . As would be expected, these assays differ with respect to their abilities to detect the two different endogenous PINP antigens in the blood, most of them preferentially reacting with the degradation product of PINP (for review, see reference
15).
Here we report the development of an assay specific for the intact, trimeric form of PINP. We first isolated the propeptide in its native state without the use of proteolytic enzymes and prepared the domain CoIl from this. The assay is now commercially available (from Orion Diagnostica, Oulunsalo, Finland) for quantifIcation of type I collagen synthesis in various diseases and physiological situations.
Materials and Methods

MATERIALS
Cell culture medium was collected from MG-63 cells (derived from a human osteosarcoma), both confluent and subconfluent. The cells were grown in Dulbecco's modified Eagle's medium supplemented with (per liter) 100 mL of newborn or fetal calf serum, 50mg of ascorbic acid, 100 kTU of penicillin, and 100mg of streptomycin, with 10 mL of medium used per 9-cmdiameter culture dish. Typically, the conditioned medium was processed in 15-L batches.
Pleural fluids were removed from patients with malignant tumors for palliative reasons. The fluids were frozen without delay and kept at -20 #{176}C until used for the purification of PINP. Upon thawing, the protease inhibitors phenylmethylsulfonyl fluoride (3 mgfL), N-ethylmaleimide (3 mg/L), p-hydroxymercuribenzoate (3 mg/L), and EDTA (10 mmol/L) were added. These fluids were pooled and typically processed in 15-L batches.
For use in the RIA, the tracer and the antiserum were diluted with 0.1 mol/L phosphate buffer, pH 7.2, containing 9 g of NaCI, 5 gof bovine serum albumin, and 0.5 gof NaN5 per liter. The separation agent (second antibody) was a suspension of goat anti-rabbit antibody covalently bound to solid particles in 0.1 molfL Tris-HCI buffer, pH 7.4, containing 9 g of NaCI, 2 g of bovine serum albumin, 1 mnL of Tween 20, and 1 g of NaN; per liter. We obtained this suspension from Orion Diagnostica.
PROCEDURES
Punfi cation of the intact propeptide. Type I procollagen was purified from the culture medium of MG-63 cells, essentially as described previously [14] . Briefly, the procollagen was digested for 16 in preparation) by intradermal injections of 50 g of the purified propeptide dissolved in 9 g/L NaCI and mixed with an equal volume of complete Freund's adjuvant. Several similar boosters were given at 3-week intervals. For the RIA, antiserum pools were made for each rabbit from several bleedings.
Purified PINP and PINP Coil were labeled with ['25ljiodine by the Chloramine T method. For PINP, the labeled protein was separated from free iodine by gel filtration on Sephacryl S-300 in phosphate-buffered saline containing 0.4 g/L Tween 20 and I g/L bovine serum albumin. For PINP Coll, this was achieved by using disposable Sep-Pak C1 reversed-phase cartridges (Waters), from which the labeled peptide bound to the cartridge packing was eluted with an equivolume solution of 2-propanol and 0.1 mol/L acetic acid [17] . surgical wound for as long as 7 days after a surgical operation. Samples of wound fluid were drawn daily by puncturing the tubing. The patients belonged to a series of patients being operated on for colorectal cancer, as described in detail previously [19] . The collection of wound fluid had been approved by the Ethical Committee of the Medical Faculty of the University of Oulu. The patients gave their informed consent to participation, and the study was carried out according to the provisions of the Declaration of Helsinki.
Results
PURIFICATION AND CHARACTERIZATION OF PINP
We first isolated PINP from type I procollagen after digestion with highly purified bacterial coilagenase.
The initial purification of PINP was based on its negative charge. In anionexchange chromatography on DEAE-Sephacel, PINP was eluted towards the end of the salt gradient, slightly ahead of the corresponding propeptide of type III procollagen. This peak was further purified by reversed-phase chromatography on HPLC. To avoid the use of proteolytic enzyme in vitro, we subsequently established the presence of high concentrations of PINP in the pleural fluids of several patients with metastasized malignant tumors and used these fluids as sources of physiologically cleaved PINP. The immunochemical properties of the propeptides-whether isolated from type I procollagen or from these pathological fluids-were identical, although the coilagenaseliberated propeptide may include the amino-terminal telopeptide of the collagen molecule proper. In gel filtration, the native PINP heterotrinier eluted as a homogeneous peak in a region corresponding to globular proteins with molecular masses of -100 kDa. PIHNP, with a molecular mass of 42 kDa and a structure analogous to that of PINP, elutes slightly earlier in the same chromatographic run. tive of the use of a reducing agent (Fig. 1) . The proa2(I) part of PINP mainly consists of collagenous helical sequence, which is known to bind protein stains only weakly. The poiypeptide profile obtained is in agreement with the chain composition of PINP, which consists of two polypeptides derived from the proctl(I) chains and one derived from the proa2(I) chain of type I procollagen, with no disulfide bonds between the chains. The apparent molecular masses, in comparison with globular standard proteins, were 28 and 14 kDa. Given the partially collagenous nature of these polypeptides, their actual molecular masses are smaller, 14 and 7 kDa, respectively. After heat denaturation (70 #{176}C, 30 mm) and a 2-h digestion with bacterial coliagenase, the larger component was greatly diminished in size, now corresponding to that of the Coil domain of PINP (Fig. 1) . The smaller component was no longer visible, the mostly collagenous peptide having been digested to small peptides that were eiuted out of the gel.
Sequencing the N-terminal amino acids of the protein was not possible without enzymatic deblocking, indicating that the aminoterminus of the protein was blocked. After deblocking, the protein was separated by reversed-phase chromatography on HPLC as described above. The major sequence obtained,
Glu-Glu-Gly-Gln-Val-Giu-Gly-Gln-Asp-Glu-Asp, agrees with the amino-terminal end of the proa 1(I) chain [20] .
RIA FOR INTACT PINP
Although polyclonal antisera to intact P1NP react with intact PINP more avidly than with the monomeric Coil domain of PINP, they show notable differences in their cross-reaction capacity with the Coil domain. For this study we selected two of the antisera. The binding of iodinated intact PINP to anti-PINP antiserum Me8 is shown in Fig. 2A, and (Fig. 6) .
In men the values tend to decrease with age (P <0.01); no such trend is evident for women, most iikeiy because of their menopausal increase in hone collagen turnover.
Discussion
The In the assay for intact PINP, most human serum samples gave inhibition curves that were superimposable with that of the authentic antigen (Fig. 3A) . The size of the immunoreactive material in serum was studied by gel filtration (Fig. 4) .
The intact PINP assay reacted only with the serum antigen eluting in the same position as the authentic intact PINP (Fig.  4A) . When the iodinated Coil domain of PINP was used as tracer in the assay, both intact and PINP Coil-related antigens reacted in approximately equal proportions (Fig. 4B) .
PINP RESPONSE IN THE HEALING WOUND
To test the validity of the PINP assay developed, we measured PINP in the interstitial fluid of a healing surgical wound, a situation involving a rapid induction of type I procoilagen synthesis, as we previously showed with the assay for PICP [19 Formaldehydetreated albumin, acetylated LDL, PIIINP I procollagen.
Intact PINP Amino-terminal the propeptides enter the circulation and reflect the rate of collagen formation in a manner analogous to that of the C peptide of proinsulin, widely used as a measure of endogenous insulin production.
We have previously established an RIA for PICP [18] , which is generally used to assess the rate of type I collagen synthesis. In the present study, we describe the establishment and biological validation of an immunoassay for the intact PINP, which was for the first time isolated without a proteolytic treatment as a native, trimeric protein. Although the molar synthesis rates of both of these propeptides are identical, they differ in their chemical structure and consequently have different metabolic fates (see Table 1 ).
The majority of the type I collagen in the body is present in the organic matrix of mineralized bone, where its synthesis is considered characteristic of an early phase in the development of the osteoblast phenotype [21] . Bone matrix is also most probably more rapidly turned over than is the rest of this collagen in soft tissues. Thus one would expect that the skeleton largely determines the circulating steady-state concentration of intact PINP. It also seems probable that complete removal of the PINP domain from the collagen molecule is necessary for the mineralization of the bone matrix, whereas in soft tissues part of the PJNP could remain attached, as is seen for PIIINP, which is found on the surface of the type III collagen fibers [4, 22] . Immunostaining of various tissues by specific immunoadsorbed antibodies to PINP has demonstrated the presence of this propeptide on collagen fibers, e.g., in skin [4, 23] , and in ovarian tissue [24] .
Previous attempts to develop assays for PINP have involved raising antibodies against synthetic peptides that represent parts of the primary sequence of a proal(I) chain, most probably because of the difficulties in isolating the native protein in large enough quantities.
None of these assays has been generally available. A PINP assay giving concentrations similar to those found here has been a result of the synthetic peptide approach [11] .However, another assay based on a synthetic peptide has been reported once in the literature, although not thoroughly characterized, and seems to give concentrations -100-fold those obtained here [10] . An important part of the validation of any procollagen propeptide assay is characterizing the serum antigens the assay recognizes.
Moreover, the behavior of the new assay in situations known to involve large changes in type I collagen synthesis must be studied thoroughly.
Much of the apparent confusion with respect to the results given by the different PINP assays is probably attributable to failure to thoroughly characterize the reaction specificities of the assays. We have recently reviewed the specificity of the various PINP assays mainly on the basis of the chemical nature of the antigen used, but not necessarily as reported by the authors [15] .
Still another assay for human PINP is based on a protein isolated from human amniotic fluid and called fetal antigen 2 (FA2) [13] , an antigen later found to he the monomeric proal(I) chain of PINP [12] . The assay recognizes two antigen forms in human serum, corresponding to those found here, but the major form measured in normal serum seems to be of the size of the degradation product [13] .As is well known forPIIINP [7, 22] , a protein quite homologous to PINP, the two antigen forms present in serum are recognized to variable extents by different antisera. Amniotic fluid PINP, however, in comparison with PINP isolated from pleural fluid, either is less stable for unknown reasons or is exposed to proteases that could remove the triple-helical central part of the molecule and thus yield monomeric fragments related to the CoIl domain. Our laboratory has previously had a similar experience with amniotic fluid PIIINP.
In both cases, this is in contrast to the remarkable stability of intact PINP and PIIINP in pleural and ascitic fluids [8] .
The present assay for intact PINP is the first and so farthe only assay that has been demonstrated to detect only the intact, trimeric form of the circulating PINP antigen. We consider this an advantage, for several reasons. First, the small degradation product may be less related to the degradation of PINP than to pN-collagen, i.e., such collagen molecules that have retained the amino-terminal propeptide and seem to he present in soft tissues but absent in mineralized bone. Secondly, the clearance of the degradation products from circulation depends on kidney function, this regulation differing from that of the hepatic clearance of the intact form. Thirdly, valid standardization and good reproducibility of the measurements can only be achieved when a homogeneous antigen is being measured. Should the specific assessment of the degradation product, PINP Coil, be necessary, it is certainly possible to develop another assay for this purpose by proper selection of the tracer antigen, imnmunogen, antiserum, and assay conditions. Ultimately the strength of a healing wound is based on collagen. Proliferation of the fibroblasts and synthesis of new collagen predominate in the proliferative phase of the healing process. We have previously shown that the induction of type I and type III collagen synthesis can be monitored by measuring the concentrations of their respective propeptides in wound fluid [19] .That system provided unequivocal evidence for the biological relevance of the assay for intact PINP presented here. The changes in the PINP concentration of the wound fluid closely mirrored those in the concentration of PICP, and similar amounts of type I procollagen formed could be calculated on the basis of the two assays. Thus, any differences between the behaviors of PINP and PICP at the serum level are likely to be due to differences in the clearances of the propeptides from the circulation or to the possible existence of biochemical variants of type I procollagen in various physiological or pathological conditions [15] . Applications of the intact PINP assay include assessing the rate of bone formation systemically [25] and determining the local rate of type I procollagen formation, e.g., in suction blister fluid of skin [26] . Moreover, somatic growth involves a high rate of turnover and deposition of type I collagen-as is reflected in high serum concentrations of PINP and PICP in infants and children, the former showing a more prominent effect of the pubertal growth spurt than the latter (Trivedi et al., unpublished data). In sera from adults the mass ratio (in p.g/L) for PICP:
PINP is 2:1-3:1, which is similar to a molar ratio of 1:1 (Table  1) . In children the mass ratio is -=0.5, gradually increasing to the adult value after puberty ([1 11, and Trivedi et al., unpublished data). The effect of menopause on serum PINP concentrations (Fig. 6 ) also seems to exceed the effect on serum PICP [18] 
